(3-chloro-6-oxopyridazin-1(6H)-yl)acetic acid → 2-(6-Oxo-1,6-dihydropyridazin-1-yl)acetic acid

HRID 713710

反応式

HRID 713710 の反応式
Cl[C:2]1[CH:7]=[CH:6][C:5](=[O:8])[N:4]([CH2:9][C:10]([OH:12])=[O:11])[N:3]=1>CO.[Pd]>[O:8]=[C:5]1[N:4]([CH2:9][C:10]([OH:12])=[O:11])[N:3]=[CH:2][CH:7]=[CH:6]1

参加物

4

反応物 1

HCID 5121297(3-chloro-6-oxopyridazin-1(6H)-yl)acetic acid

生成物 1

HCID 14155362-(6-Oxo-1,6-dihydropyridazin-1-yl)acetic acid

試薬・触媒・溶媒 2

HCID 23938Palladium触媒HCID 887Methanol溶媒

実験手順

[3-Chloro-6-oxopyridazin-1(6H)-yl]acetic acid (1.00 g, 5.30 mmol) in methanol (40 mL) was added 100 mg of 10% Pd/C. After the reaction mixture was stirred at ambient temperature under a H2 balloon for 1 h, the Pd was filtered off through celite. The filtrate was concentrated in vacuo and purified by reverse phase HPLC (TMC Pro-Pac C18; 0-40% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). Removal of the volatiles in vacuo afforded the title compound as a white crystalline. 1H NMR (D2O): δ 8.06 (dd, J=3.9, 1.4 Hz, 1H), 7.56 (dd, J=9.4, 3.9 Hz, 1H), 7.12 (dd, J=9.4, 1.5 Hz, 1H), 4.95 (s, 2H). LC/MS 155.2 (M+1).

後処理

  1. filtrationthe Pd was filtered off through celite
  2. concentrationThe filtrate was concentrated in vacuo
  3. custompurified by reverse phase HPLC (TMC Pro-Pac C18; 0-40% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient)
  4. customRemoval of the volatiles in vacuo

出典と根拠

ORDレコード
ord-4553935253964522beebfc9925035ec3
出典データセット
uspto-grants-2015_11
特許番号
US09186354B2

関連ノート

読み込み中…